LeonaBio, Inc. Stock-Based Compensation
LeonaBio, Inc. (LONA) reported Stock-Based Compensation of $3.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- LeonaBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.18M, a 99.19% increase year-over-year.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $662.00K, a 59.56% decline year-over-year.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.46M, a 34.59% decline year-over-year.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.41M, a 51.98% decline year-over-year.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.10M, a 44.77% decline from fiscal 2024.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $11.05M, a 4.01% increase from fiscal 2023.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $10.62M, a 0.16% increase from fiscal 2022.
- LeonaBio, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $10.61M, a 129.42% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.84M 10-Q · filed 2026-08-14 | $5.30M derived: sum of 3 quarters · filed 2026-08-14 | $6.71M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $662.00K 10-Q · filed 2026-05-07 | $2.12M derived: sum of 2 quarters · filed 2026-05-07 | $3.53M derived: sum of 3 quarters · filed 2026-05-07 | $5.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.87M derived: sum of 2 quarters · filed 2026-03-31 | $4.46M derived: sum of 3 quarters · filed 2026-08-14 | $6.10M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.01M derived: sum of 2 quarters · filed 2026-08-14 | $4.64M 10-Q · filed 2025-11-06 | $6.87M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.23M 10-Q · filed 2026-08-14 | $5.46M derived: sum of 3 quarters · filed 2026-08-14 | $8.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.64M 10-Q · filed 2026-05-07 | $3.87M derived: sum of 2 quarters · filed 2026-05-07 | $6.80M derived: sum of 3 quarters · filed 2026-05-07 | $10.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.17M derived: sum of 2 quarters · filed 2026-03-31 | $8.37M derived: sum of 3 quarters · filed 2026-03-31 | $11.05M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.14M derived: sum of 2 quarters · filed 2025-11-06 | $8.82M 10-Q · filed 2025-11-06 | $11.05M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.88M 10-Q · filed 2025-08-07 | $8.11M derived: sum of 3 quarters · filed 2025-08-07 | $10.61M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.68M 10-Q · filed 2025-05-09 | $4.91M derived: sum of 2 quarters · filed 2025-05-09 | $7.40M derived: sum of 3 quarters · filed 2025-05-09 | $10.52M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.72M derived: sum of 2 quarters · filed 2025-02-27 | $7.84M derived: sum of 3 quarters · filed 2025-02-27 | $10.62M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.61M derived: sum of 2 quarters · filed 2024-11-07 | $8.39M 10-Q · filed 2024-11-07 | $10.76M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.90M 10-Q · filed 2024-08-01 | $8.26M derived: sum of 3 quarters · filed 2024-08-01 | $10.68M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $2.78M 10-Q · filed 2024-05-15 | $5.14M derived: sum of 2 quarters · filed 2024-05-15 | $7.56M derived: sum of 3 quarters · filed 2024-05-15 | $10.66M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $4.78M derived: sum of 2 quarters · filed 2024-02-22 | $7.88M derived: sum of 3 quarters · filed 2024-02-22 | $10.61M 10-K · filed 2024-02-22 |
| 2022-09-30 | $2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.51M derived: sum of 2 quarters · filed 2023-11-09 | $8.25M 10-Q · filed 2023-11-09 | $9.68M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.83M 10-Q · filed 2023-08-10 | $7.26M derived: sum of 3 quarters · filed 2023-08-10 | $8.37M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.73M 10-Q · filed 2023-05-11 | $4.17M derived: sum of 2 quarters · filed 2023-05-11 | $5.27M derived: sum of 3 quarters · filed 2023-05-11 | $6.38M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.54M derived: sum of 2 quarters · filed 2023-03-23 | $3.65M derived: sum of 3 quarters · filed 2023-03-23 | $4.62M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.21M derived: sum of 2 quarters · filed 2022-11-10 | $3.19M 10-Q · filed 2022-11-10 | $3.60M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.08M 10-Q · filed 2022-08-15 | $2.50M derived: sum of 3 quarters · filed 2022-08-15 | $2.61M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $974.00K 10-Q · filed 2022-05-12 | $1.39M derived: sum of 2 quarters · filed 2022-05-12 | $1.50M derived: sum of 3 quarters · filed 2022-05-12 | $1.55M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $526.00K derived: sum of 2 quarters · filed 2022-03-28 | $575.00K derived: sum of 3 quarters · filed 2022-03-28 | $633.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $160.00K derived: sum of 2 quarters · filed 2021-11-10 | $218.00K 10-Q · filed 2021-11-10 | $282.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $107.00K 10-Q · filed 2021-08-16 | $171.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $58.00K 10-Q · filed 2021-05-13 | $122.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $253.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $189.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |